The Europe Actinic Keratosis Treatment Market should witness market growth of 4.1% CAGR during the forecast period (2022-2028).
A multitude of factors is taken into account when developing a treatment strategy for AK. These include characteristics and symptoms of AK, the patient's expectations, and the availability of treatments, the patient's capacity to adhere to treatment regimens, the tolerability of side effects, and the cost of treatments.
When lesions are many, bleeding, painful, and/or expanding quickly in size, it is a sign of urgency. Utilizing specialized tools to scrape away and burn (electrodessicate) the AK base is known as electrodesication and curettage. This procedure is repeated multiple times to get rid of all the AK and create clear margins. There are several possible topical alternatives like drugs and topically applicable creams or gels.
Applying a lotion or gel to the exposed lesions is known as a topical treatment. If there are multiple AKs in one region, this strategy might be employed. The drug causes a skin reaction that kills the AKs after being applied for a predetermined period of time. Topical medications typically cause the skin to become red, although they are quite powerful. Several research studies on less abrasive topical therapies for actinic keratosis are being conducted as well.
The expansion of AK treatments in this region is fueled by the rising number of actinic keratosis instances that have been documented and rising medical tourism. Due to the high incidence of actinic keratosis and the rising popularity of minimally invasive procedures, the demand has significantly grown in the United Kingdom. The affordable actinic keratosis treatment as well as advantageous Medicaid and Medicare reimbursements also impact the preference for AK treatment.
The Germany market dominated the Europe Actinic Keratosis Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $527.3 Million by 2028. The UK market is experiencing a CAGR of 3.3% during (2022-2028). Additionally, The France market would experience a CAGR of 4.9% during (2022-2028).
Based on Drug Class, the market is segmented into Nucleoside Metabolic Inhibitor, NSAIDs, Immune Response Modifiers, Photoenhancers and Others. Based on Therapy, the market is segmented into Surgery, Topical and Photodynamic Therapy. Based on End-use, the market is segmented into Hospitals, Private Clinics, Homecare and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Almirall, S.A, LEO Pharma A/S, Biofrontera AG, Sun Pharmaceuticals Industries Ltd., 3M Company, Bausch Health Companies, Inc., Novartis AG, Viatris, Inc., and Galderma S.A.
A multitude of factors is taken into account when developing a treatment strategy for AK. These include characteristics and symptoms of AK, the patient's expectations, and the availability of treatments, the patient's capacity to adhere to treatment regimens, the tolerability of side effects, and the cost of treatments.
When lesions are many, bleeding, painful, and/or expanding quickly in size, it is a sign of urgency. Utilizing specialized tools to scrape away and burn (electrodessicate) the AK base is known as electrodesication and curettage. This procedure is repeated multiple times to get rid of all the AK and create clear margins. There are several possible topical alternatives like drugs and topically applicable creams or gels.
Applying a lotion or gel to the exposed lesions is known as a topical treatment. If there are multiple AKs in one region, this strategy might be employed. The drug causes a skin reaction that kills the AKs after being applied for a predetermined period of time. Topical medications typically cause the skin to become red, although they are quite powerful. Several research studies on less abrasive topical therapies for actinic keratosis are being conducted as well.
The expansion of AK treatments in this region is fueled by the rising number of actinic keratosis instances that have been documented and rising medical tourism. Due to the high incidence of actinic keratosis and the rising popularity of minimally invasive procedures, the demand has significantly grown in the United Kingdom. The affordable actinic keratosis treatment as well as advantageous Medicaid and Medicare reimbursements also impact the preference for AK treatment.
The Germany market dominated the Europe Actinic Keratosis Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $527.3 Million by 2028. The UK market is experiencing a CAGR of 3.3% during (2022-2028). Additionally, The France market would experience a CAGR of 4.9% during (2022-2028).
Based on Drug Class, the market is segmented into Nucleoside Metabolic Inhibitor, NSAIDs, Immune Response Modifiers, Photoenhancers and Others. Based on Therapy, the market is segmented into Surgery, Topical and Photodynamic Therapy. Based on End-use, the market is segmented into Hospitals, Private Clinics, Homecare and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Almirall, S.A, LEO Pharma A/S, Biofrontera AG, Sun Pharmaceuticals Industries Ltd., 3M Company, Bausch Health Companies, Inc., Novartis AG, Viatris, Inc., and Galderma S.A.
Scope of the Study
By Drug Class
- Nucleoside Metabolic Inhibitor
- NSAIDs
- Immune Response Modifiers
- Photoenhancers
- Others
By Therapy
- Surgery
- Topical
- Photodynamic Therapy
By End-use
- Hospitals
- Private Clinics
- Homecare
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Almirall, S.A
- LEO Pharma A/S
- Biofrontera AG
- Sun Pharmaceuticals Industries Ltd.
- 3M Company
- Bausch Health Companies, Inc.
- Novartis AG
- Viatris, Inc.
- Galderma S.A.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Europe Actinic Keratosis Treatment Market by Drug Class
Chapter 4. Europe Actinic Keratosis Treatment Market by Therapy
Chapter 5. Europe Actinic Keratosis Treatment Market by End-use
Chapter 6. Europe Actinic Keratosis Treatment Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Almirall, S.A
- LEO Pharma A/S
- Biofrontera AG
- Sun Pharmaceuticals Industries Ltd.
- 3M Company
- Bausch Health Companies, Inc.
- Novartis AG
- Viatris, Inc.
- Galderma S.A.
Methodology
LOADING...
